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Abstract: Photodynamic therapy is a relatively new modality of cancer treatment in human and veterinary 
medicine. It uses a photosensitizing drug called photosensitizer; which in the presence of oxygen delivers reactive 
species (singlet oxygen and free radicals) upon irradiation of the tumor with visible light. In contrast to classical 
chemotherapy; the original compound (sensitizer or photosensitizer) has a minimal toxic effect on the whole body. 
Its effect is due to the activation of the accumulated sensitizer in a given tissue by visible light around 630 nm 
wavelength or above. Excitation by light produces activated oxygen- and nitrogen species; which are able to rapidly 
kill cells. No harming radiation is involved. The administered compound gets activated only in the illuminated area; 
mainly killing actively dividing cells. The treatment achieves its selectivity by illuminating only the area affected 
by the tumor. Apparently; it does not solve the problem of metastasis; but offers many advantages against 
chemotherapy; radiation or surgery. PDT offers an additional method to treat patients with certain kinds of cancer. 
Here we present some preliminary data on the application of PDT on companion animals with malignant tumors. 
We have applied 5-aminolevulinic acid (ALA)-based PDT on cats and dogs with different kinds of tumors; and 
investigated the effect of treatment on reduction-oxidation parameters of tissue samples taken from the tumors 
before and after PDT. Results of free radical concentrations measured using Electron Spin Resonance and of 
reduced glutathione in tumor tissues give a direct correlation with the outcome of PDT. 
 
INTRODUCTION 
 
Photodynamic therapy (PDT) is a treatment approved by US Food and Drug 
Administration for various types of human cancer [2; 12; 13]. A light-sensitive drug 
(photosensitizer) is administered or applied to the patient; followed by illumination with laser 
or halogen lamp emitting visible light of 630 nm wavelength or slightly above; which  
matches the photophysical properties of the sensitizing drug. Interaction with the light 
activates the photosensitizer; which in the presence of molecular oxygen produces reactive 
species like singlet oxygen and free radicals causing destruction of the target tumor.  
Photosensitizers are preferentially taken up by the tumor and without being activated by 
light; are usually not harmful to tissues; have very low toxicity. The light used to activate the 
drug is also harmless on its own; so specificity of the treatment is achieved by illuminating 
only the area affected by cancer. Tissue damaging effect is seen when all three components 
are present simultaneously: photosensitizer; visible light and oxygen. Unlike in chemotherapy; 
it is not the photosensitizing drug that induces cell death; but the reactive species produced 
during reaction of excited sensitizer with molecular oxygen. The photoproducts react with 
different molecules found in cellular organelles disrupting membranes and bioenergetic 
pathways causing cell death [8]. PDT has been shown to be an effective treatment modality 
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for surface-oriented neoplasms of the skin; respiratory; gastrointestinal; and urogenital 
systems both in humans and animals (see Fig. 1 as an example of the later).  
While first veterinary studies were contemporary with human clinical trials in the 
early eighties; thousands of human cancer patients have undergone PDT up to the present; 
whereas not many veterinary patients have received it [8]. Dogs and cats with certain 
types of tumors; for example spontaneous squamous cell carcinomas (SCC); share striking 
similarities with humans affected with same types of cancer; thus research results obtained 
in companion animals are directly applicable to humans [9;11].  
The reduction-oxidation status of many tumors differs from that of healthy cells. PDT 
produces reactive species like singlet oxygen and superoxide anion radicals; which in turn; 
may alter the redox and bioenergetic cellular pathways. Antioxidants may interfere or enhance 
the effect of PDT depending on their dose; light fluence and other factors [5; 7].  Our research 
team studied changes in free radical and reduced glutathione (GSH) concentrations related to 
PDT in order to find relationships between the tumor redox status and the outcome of 5-
aminolevulinic acid (ALA)-based PDT in companion animals with different types of tumors. 
 
MATERIALS AND METHODS 
 
Chemicals were purchased from Sigma-Aldrich Co. (Budapest; Hungary) unless 
indicated otherwise. Three cats and one dog with naturally occurring carcinomas were entered 
into the study.  Patient 1: 11-year old male cat with a medium-grade malignant fibrosarcoma 
on its left flank (approx. 2 cm diameter; noninvasive; stage I); Patient 2: 10-year old male cat 
with a medium-grade malignant fibrosarcoma on the spine (approx. 5 cm diameter; 
noninvasive; stage II); Patient 3: 17-year old castrated male cat with a high-grade malignant; 
ulcerated and inflamed fibrosarcoma on its right front limb (approx. 2 cm diameter; invasive; 
stage II); treated twice by surgery before; Patient 4: 5-year old boxer bitch with a 
mastocytoma on its right front paw (approx. 3.5 cm diameter; noninvasive; stage II). 
For mastocytoma; we used the WHO Clinical Staging System for Mast Cell Tumors [3] 
and for sarcoma the Modified Staging System for Canine Soft Tissue Sarcomas [10] Routine 
clinical and hematological analyses were performed using diagnostic kits in the laboratory of 
the Department of Internal Medicine and Clinics; Faculty of Veterinary Science; Szent István 
University. Biochemical test kits were purchased from Diagnosticum Ltd. (Budapest; 
Hungary); and routine hematology data were assessed by an ADVIA 120 automatic laser 
beam cell analyzer (Bayer Co.) and blood smear evaluation. Photodynamic therapy was 
delivered to the tumors using a 250 W halogen lamp (Teclas; Switzerland) 3 hours after i.v. 
administration of 60 mg/kg photosensitizer ALA (Fluka; Germany).   
Irradiation was performed at a 100 J/cm2 light-dose using a non-coherent light source at 
a wavelength of 610-728 nm. PDT was repeated within 2 weeks; with exception of Patient 3; 
which received a third treatment 10 weeks after the second PDT. Following treatment; 
effectiveness of PDT was evaluated according to tumor size changes and histopathological 
results. Histopathology was performed by the conventional method of hematoxylin-eosin 
staining of paraffin-embedded tumor samples. GSH concentrations of tumor tissues were 
measured based on the original method of Kosower et al. [6]; while free radical 
concentrations were determined using an X-band electron spin resonance (ESR) spectrometer 
constructed by Magnettech GmbH (Berlin; Germany); described by us earlier [14]. 
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RESULTS AND DISCUSSION 
 
ALA is a naturally occurring compound in the hem biosynthetic pathway; which is 
metabolized to a photosensitive product; protoporphyrin IX (PpIX). Clinical or hematological 
evidence of toxicity was not seen in any animal following administration of the 
photosensitizer precursor. Patients 2 and 4 gave a poor response to PDT as their tumors kept 
growing after the treatment. Patient 2 with a large-size soft tissue sarcoma was later on 
referred to chemotherapy; and patient 4 with mastocytoma to radiotherapy.  
Both gave partial response to these posterior treatments (data not presented). Patient 1 
gave a response of about 50% to PDT as the size of its tumor has been reduced significantly. 
No conclusive results could be obtained though; as four days after the second PDT the 
patient’s general state started to deteriorate abruptly for unknown reasons; and was euthanized 
a few days later. Patient 3 gave very good response to PDT combined with reductive surgery: 
intensive epithelization and complete wound healing could be observed 6 weeks after the first 
PDT. The tumor recurred a few weeks later; when a third PDT was performed. The response 
was complete; but the tumor recurred one more time on a site untouched by PDT. 
 
Fig. 1. Photodynamic therapy of a fibrosarcoma on the front 
limb of a cat. (A) Before PDT. (B) Three hours after intravenous 
photosensitizer administration and reductive surgery; the tumor 
was illuminated by visible light. (C) Six weeks after PDT; 
epithelization and hair re-growth can be observed. 
 
Tumor biopsies taken before every PDT were 
analyzed; where possible; for their total free radical and 
GSH concentrations. It has been shown by us 
previously that cancerous canine lymph nodes 
contained higher free radical and lower GSH levels 
than those of healthy dogs. In addition; higher levels of 
free radicals correlated well with the proliferating 
index of tumors [14]; indicating that tumors producing 
more free radicals are in a higher proliferative stage. 
Total free radical concentration was measured by ESR 
spectroscopy and Figure 2 shows a typical spectrum of 
the tumor tissue taken before and after PDT.   
The area between the two standard manganese 
peaks; under the sigmoid spectrum was double 
integrated and corrected for a blank to get quantitative 
measurements of the steady state free radical 
concentration of a given tissue sample. GSH is the 
most abundant water soluble antioxidant in the cell and 
has been shown to have protective properties against 
side effects; as well as a good ability to improve the 
efficacy of chemotherapy in cancer [1]. Its 
concentration is an indicative factor of the oxidative 
stress present in any healthy or tumor tissue. 
Figure 3A shows the results of total free radical 
and GSH analyses of tumor biopsies taken from 
patients before and after PDT treatments.  
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Fig. 2. ESR spectra showing steady state free 
radical concentration of a tumor sample taken from 
patient 1 before (A) and after (B) first PDT. 
Spectrum contains two manganese peaks indicated 
by arrows; which serve as internal standards. The 
signal between two manganese peaks was double 
integrated for quantification. 
 
In patients 1 and 3 the concentration of 
free radicals decreased after the first PDT; 
while the levels of GSH showed a significant 
increase. No similar changes could be 
observed in patients 2 and 4; which gave 
poor or no response to PDT.  Unfortunately; 
patient 3 showed a recurrence of its tumor 
after the second PDT; and had to be given a 
third treatment. Its tumor behavior is 
reflected in the partial reversal seen in the changes of the measured free radical and GSH 
concentrations.  
 
 
Fig. 3. A. Levels of steady 
state free radical and GSH 
concentrations measured in four 
different patients before and after 
PDT. 
 
Histopathology of the 
tumor samples of patients 
supported the general 
observation on the effectiveness 
of PDT. Fig. 3B shows a section 
of the sarcoma tissue before 
PDT with massive infiltration of 
highly mitotic tumor cells (a); 
while (b) shows mainly dead 
cells after PDT with some viable ones on the periphery. 
 
 
 
Fig. 3. B. Histopathological sample staining 
obtained from tumor of patient 1 before (a) and after (b) PDT. 
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CONCLUSIONS 
 
We have presented preliminary results on our first attempts to introduce PDT into the 
veterinary medicine in Hungary. Total free radical/GSH ratio gives a good indication of the 
oxidative status of a tissue. Tumors with different initial free radical/GSH levels gave 
different responses to PDT indicating no intrinsic relationship between the tumor redox status 
measured before the treatment and the outcome of ALA-PDT. The effectiveness of PDT 
correlated with the free radical and GSH levels measured after PDT; indicating a good 
accordance between the outcome of the treatment and a favorable oxidant/antioxidant status 
of the tissue.  PDT represents a promising treatment modality and will most likely play a 
more significant role in the future of veterinary medicine; especially after appropriate 
treatment protocols will be established for different types of tumors. In our case; no large 
tumors responded well to PDT as the efficacy of the treatment is limited by light penetration 
(about 1 cm at 600-700 nm). Smaller-sized tumors usually respond much better to a single 
treatment.  We also have to emphasize; that we treated tumors in their very advanced and 
neglected stage; when no real cure could be expected. Qualitative data obtained on the 
correlation between total free radical/GSH concentrations and the outcome of PDT suggests 
the possibility of a good prognostic value for evaluating the effectiveness of the treatment. 
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